Potential Metabolic Pathways Involved in Osteoporosis and Evaluation of Fracture Risk in Individuals with Diabetes
- PMID: 38884020
- PMCID: PMC11178402
- DOI: 10.1155/2024/6640796
Potential Metabolic Pathways Involved in Osteoporosis and Evaluation of Fracture Risk in Individuals with Diabetes
Abstract
Diabetes has a significant global prevalence. Chronic hyperglycemia affects multiple organs and tissues, including bones. A large number of diabetic patients develop osteoporosis; however, the precise relationship between diabetes and osteoporosis remains incompletely elucidated. The activation of the AGE-RAGE signaling pathway hinders the differentiation of osteoblasts and weakens the process of bone formation due to the presence of advanced glycation end products. High glucose environment can induce ferroptosis of osteoblasts and then develop osteoporosis. Hyperglycemia also suppresses the secretion of sex hormones, and the reduction of testosterone is difficult to effectively maintain bone mineral density. As diabetes therapy, thiazolidinediones control blood glucose by activating PPAR-γ. Activated PPAR-γ can promote osteoclast differentiation and regulate osteoblast function, triggering osteoporosis. The effects of metformin and insulin on bone are currently controversial. Currently, there are no appropriate tools available for assessing the risk of fractures in diabetic patients, despite the fact that the occurrence of osteoporotic fractures is considerably greater in diabetic individuals compared to those without diabetes. Further improving the inclusion criteria of FRAX risk factors and clarifying the early occurrence of osteoporosis sites unique to diabetic patients may be an effective way to diagnose and treat diabetic osteoporosis and reduce the risk of fracture occurrence.
Copyright © 2024 Tong Liu et al.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Activation of osteoblast ferroptosis via the METTL3/ASK1-p38 signaling pathway in high glucose and high fat (HGHF)-induced diabetic bone loss.FASEB J. 2022 Mar;36(3):e22147. doi: 10.1096/fj.202101610R. FASEB J. 2022. PMID: 35104016
-
Role of nitric oxide in type 1 diabetes-induced osteoporosis.Biochem Pharmacol. 2022 Mar;197:114888. doi: 10.1016/j.bcp.2021.114888. Epub 2021 Dec 28. Biochem Pharmacol. 2022. PMID: 34968494 Review.
-
Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.Med Hypotheses. 2005;65(6):1013-5. doi: 10.1016/j.mehy.2005.07.017. Med Hypotheses. 2005. PMID: 16146671
-
Impact of diabetes and its treatments on skeletal diseases.Front Med. 2013 Mar;7(1):81-90. doi: 10.1007/s11684-013-0243-9. Epub 2013 Feb 2. Front Med. 2013. PMID: 23377889 Review.
-
Diabetes and bone health.Maturitas. 2013 Nov;76(3):253-9. doi: 10.1016/j.maturitas.2013.04.004. Epub 2013 Apr 28. Maturitas. 2013. PMID: 23628280 Review.
Cited by
-
Does Improvement of Glycemic Control Cause Acute Charcot Foot in Patients with Diabetes?Exp Clin Endocrinol Diabetes. 2025 Mar;133(3):120-132. doi: 10.1055/a-2498-6826. Epub 2025 Jan 22. Exp Clin Endocrinol Diabetes. 2025. PMID: 39842459 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials